The short version of peptide mapping fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-19 and is reviewed periodically as new material appears.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
== External links == Pharmaceutical Inspection Cooperation Scheme: GMP Guides World Health Organization GMP Guidelines European Union GMP Guidelines US CFR Title 21 parts 210 (GMP, general), 211 (GMP, finished pharmaceuticals), 212 (GMP, positron emission tomography drugs), 225 (GMP, medicated feeds), 226 (GMP, type A medicated articles). Report on Optimizing and Leaning GMP Batch Record Design
Mann, Adam (20 April 2021). "Making headway with the mysteries of life's origins". Proceedings of the National Academy of Sciences. 118 (16) e2105383118. doi:10.1073/pnas.2105383118. PMC 8072247. PMID 33853953. Exploring Life's Origins Archived 8 April 2023 at the Wayback Machine a virtual exhibit at the Museum of Science (Boston) How life began on Earth – Marcia Malory (Earth Facts; 2015) The Origins of Life – Richard Dawkins et al. (BBC Radio; 2004) Life in the Universe – Essay by Stephen Hawking (1996)
During the Qing dynasty, China opened itself to foreign trade under the Canton System through the port of Guangzhou (Canton), with traders from the East India Company visiting the port by the 1690s. Due to the growing British demand for Chinese tea and the Chinese Emperor's lack of interest in British commodities other than silver, British traders resorted to trade in opium as a high-value commodity for which China was not self-sufficient. The English traders had been purchasing small amounts of opium from India for trade since Ralph Fitch first visited in the mid-16th century. Trade in opium was standardized, with production of balls of raw opium, 1.1–1.6 kg (2.4–3.5 lb), 30% water content, wrapped in poppy leaves and petals, and shipped in chests of 60–65 kg (132–143 lb) (one picul). Chests of opium were sold in auctions in Calcutta with the understanding that the independent purchasers would then smuggle it into China. China had a positive balance sheet in trading with the British, which led to a decrease of the British silver stocks. Therefore, the British tried to encourage Chinese opium use to enhance their balance, and they delivered it from Indian provinces under British control. In India, its cultivation, as well as the manufacture and traffic to China, were subject to the British East India Company (BEIC), as a strict monopoly of the British government. There was an extensive and complicated system of BEIC agencies involved in the supervision and management of opium production and distribution in India.
=== Lifetime cumulative dose === Bleomycin should not exceed a lifetime cumulative dose greater than 400 units. Pulmonary toxicities, most commonly presenting as pulmonary fibrosis, are associated with doses of bleomycin greater than 400 units.
Sources: en.wikipedia.org
is electron mobility E is the electric field across the depletion region Dn is the diffusion coefficient for electrons Gn is the rate of generation of electrons Rn is the rate of recombination of electrons Similarly, for holes:
== Structure == Human gamma-actin is 41.8 kDa in molecular weight and 375 amino acids in length. Actins are highly conserved proteins that are involved in various types of cell motility, and maintenance of the cytoskeleton. In vertebrates, three main groups of actin paralogs, alpha, beta, and gamma, have been identified. The alpha actins are found in muscle tissues and are a major constituent of the sarcomere contractile apparatus. The beta and gamma actins co-exist in most cell types as components of the cytoskeleton, and as mediators of internal cell motility. Actin, gamma 1, encoded by this gene, is found in non-muscle cells in the cytoplasm, and in muscle cells at costamere structures, or transverse points of cell-cell adhesion that run perpendicular to the long axis of myocytes.
Nigeria is home to two of the few hospitals in the world that focus on treating noma patients: Sokoto Noma Hospital, in the city of Sokoto, and the Noma Centre Abuja (built and funded by the Noma Aid Nigeria Initiative) in 2022 . In January 2023 the Nigerian Ministry of Health submitted to the World Health Organization a request for noma to be added to WHO's list of neglected tropical diseases. This had been endorsed by 31 countries, and was accompanied by a dossier of evidence demonstrating that noma fit the criteria for inclusion. In December 2023 WHO conceded the request. It is hoped that this will encourage more research into the disease.
ferredoxin–nicotinamide adenine dinucleotide reductase ferredoxin reductase NAD+-ferredoxin reductase ferredoxin–NAD+ reductase ferredoxin–linked NAD+ reductase ferredoxin–NAD reductase When NAD molecule is in its reduced form, the enzyme is referred to as:
DNA replication in variola virus takes place within the cytoplasm of the infected cell. Recombination of the genome occurs within actively infected cells. The products include transcription factors for transcribing genes for new virions, as well as viral RNA polymerase and other essential enzymes for new viral particles. These proteins are packaged into new infectious virions.
Sources: en.wikipedia.org
== In culture == The jalapeño is a Mexican chili but was designated by the Texas Legislature as the official "State Pepper of Texas" in 1995. In Mexico, jalapeños are used in many forms such as in salsa, pico de gallo, or grilled jalapeños. Jalapeños were included as food on the Space Shuttle as early as 1982. Guinness World Records recognizes Alfredo Hernandes for the most jalapeños eaten in a minute: 16, on 17 September 2006 at the La Costeña Feel the Heat Challenge in Chicago, Illinois. Patrick Bertoletti holds the Major League Eating jalapeño records at 275 pickled jalapeños in 8 minutes on 1 May 2011, and 191 pickled jalapeños in 6.5 minutes on 16 September 2007 in the 'Short-Form'. Joaquín Guzmán, also known as "El Chapo", the leader of the Sinaloa Cartel, operated a cannery in Guadalajara producing "Comadre Jalapeños" in order to ship cocaine to the US. The official mascot of the 1986 FIFA World Cup was Pique, a jalapeño pepper, characteristic of Mexican cuisine, with a moustache, a Colimote sombrero, and Mexican football team colors. Its name comes from picante, a Spanish word meaning "spicy", and was also a pun on the "PK" abbreviation of the football term penalty kick. Pique is also a common Spanish name. September 5th is recognized as National Jalapeno Day.
=== Other uses in mathematics, science, and technology === Cauchy–Riemann equations, partial differential equations describing complex differentiability CR manifold, a type of differentiable manifold Chromium, symbol Cr, a chemical element Cr or CR, an improper designation given to astronomical objects in the Collinder catalog of open clusters from Collinder 1–471 Change request, a document containing a call for an adjustment of a system Compression ratio, the ratio of the volume of a combustion chamber from its largest capacity to its smallest capacity Concentration ratio, in economics Conjugate residual method, an iterative numeric method used for solving systems of linear equations Complex resistivity (measurement method), in geophysics Cosmic rays
== Sultanate and Kingdom of Egypt == The Order was established in 1915 by Sultan Hussein Kamel of Egypt for award to persons who had rendered useful service to the country. It ranked beneath the Order of Ismail and was frequently awarded to British officers and officials serving in Egypt, as well as distinguished Egyptian citizens.The order comprised five classes:
A study of Temnothorax nylanderi colonies in Germany found that workers parasitized by the tapeworm Anomotaenia brevis (ants are intermediate hosts, the definitive hosts are woodpeckers) lived much longer than unparasitized workers and had a reduced mortality rate, comparable to that of the queens of the same species, which live for as long as two decades. South American poison dart frogs in the genus Dendrobates feed mainly on ants, and the toxins in the skin of some species come from the ants. Formicine ants in the genera Brachymyrmex and Paratrechina have been found to contain pumiliotoxin found in Dendrobates pumilio. The West African frog Phrynomantis microps is able to move within the nests of Paltothyreus tarsatus ants, producing peptides on its skin that prevent the ants from stinging them. Army ants forage in a wide roving column, attacking any animals in that path that are unable to escape. In Central and South America, Eciton burchellii is the swarming ant most commonly attended by "ant-following" birds such as antbirds and woodcreepers. This behaviour was once considered mutualistic, but later studies found the birds to be parasitic. Direct kleptoparasitism (birds stealing food from the ants' grasp) is rare and has been noted in Inca doves which pick seeds at nest entrances as they are being transported by species of Pogonomyrmex. Birds that follow ants eat many prey insects and thus decrease the foraging success of ants. Birds indulge in a peculiar behaviour called anting that, as yet, is not fully understood.
=== Sightings === The investigation into the child's disappearance was slow to commence and soon slowed down further due to the lack of credible leads. Nevertheless, the case had sparked public interest to a degree that sightings of Mendonça were numerous over the years since his disappearance. A prostitute, Alcina Dias, confirmed that Afonso had taken Mendonça to see her on the day he disappeared. Dias allegedly drove up to see her in his car and asked her if she was working. When she assented, he offered to pay her to have sex with Mendonça. Alcina Dias said that Mendonça was extremely nervous and crying by the time he exited the vehicle, reportedly saying that Afonso had forced him to meet her. Alcina Dias added that she tried to calm the boy down and asked him if his mother knew he was there, to which the boy replied no. Mendonça then allegedly drove off in Afonso's vehicle. Alcina Dias allegedly tried to give her deposition to the authorities, but could never identify Dias by name. In 2011, she finally identified him in a court of law. In April 1998, the political commentator Nuno Rogeiro traveled to Disneyland Paris with his family. During the trip, the Rogeiro family snapped several photographs whilst on a ride; one of these photos depicts a boy sitting behind the family who reportedly looks remarkably like Mendonça. Sitting next to the boy was a man in his 40s wearing a red jacket. The Portuguese police did confiscate the photographs for further analysis, but no further progress was made regarding this sighting.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.